SYRE CIK: 1636282

Spyre Therapeutics, Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25

Assets

(positive)
Change from FY21 to FY25
billions USD
FY21:
0.10
FY22:
0.06
FY23:
0.34
FY24:
0.61
FY25:
0.78
(positive)
Change from FY21 to FY25
billions USD
FY21:
0.01
FY22:
0.01
FY23:
0.00
FY24:
0.00
FY25:
0
Total assets
Change from FY21 to FY25
billions USD
FY21:
0.11
FY22:
0.07
FY23:
0.34
FY24:
0.61
FY25:
0.78

Liabilities & Equity

(negative)
Change from FY21 to FY25
billions USD
FY21:
0.02
FY22:
0.01
FY23:
0.03
FY24:
0.05
FY25:
0.06
(negative)
Change from FY21 to FY25
billions USD
FY21:
0.01
FY22:
0.01
FY23:
0.04
FY24:
0.04
FY25:
0.00
(positive)
Change from FY21 to FY25
billions USD
FY21:
0.08
FY22:
0.05
FY23:
0.18
FY24:
0.52
FY25:
0.72
Total liabilities & equity
Change from FY21 to FY25
billions USD
FY21:
0.11
FY22:
0.07
FY23:
–
FY24:
0.61
FY25:
0.78

All amounts in billions USD Data source:SEC EDGAR